Point72 Asset Management
PACB icon

Point72 Asset Management’s Pacific Biosciences PACB Stock Holding History

Point72 Asset Management’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-200,000
Closed -$750K – 2298
2024
Q1 		$750K Buy
+200,000
New +$1.17M ﹤0.01% 1532

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management's PACB Position: Q1 2026 in Review

Point72 Asset Management reduced its Pacific Biosciences (PACB) stake by 90% in Q1 2026, selling an estimated $4.78M and leaving 285,700 shares worth $377K. The position accounts for ﹤0.01% of the portfolio, ranked #3262.

Point72 Asset Management first reported a position in PACB in Q2 2015 and has held it in 19 quarters since. The position peaked at $88.6M in Q2 2023. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Point72 Asset Management held 285,700 shares of Pacific Biosciences worth $377K as of Q1 2026.
  • Point72 Asset Management sold 2,671,700 Pacific Biosciences shares in Q1 2026, an estimated $4.78M.
  • Pacific Biosciences made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #3262 holding.
  • Point72 Asset Management first reported a position in Pacific Biosciences in Q2 2015 and has held it in 19 quarters since.
  • Point72 Asset Management's Pacific Biosciences position peaked at $88.6M in Q2 2023.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.